Health CatalystHCAT +3.43%44 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates HCAT with a GF Score™ of 44/100 and a GF Value™ of $5.06 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 581 Healthcare Providers & Services companies, Health Catalyst ranks worse than 172116.87% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Health Catalyst's annualized net income for the quarter that ended in Mar. 2026 was $-444.1 Mil. Health Catalyst's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-42.7 Mil. Therefore, Health Catalyst's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Health Catalyst's Return-on-Tangible-Equity or its related term are showing as below:
HCAT's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 9.93 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Health Catalyst (NAS:HCAT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Health Catalyst Return-on-Tangible-Equity Related Terms
Health Catalyst Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Health Catalyst's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCAT vs SY, AMWL, OPRX: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Health Catalyst's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health Catalyst Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health Catalyst's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Health Catalyst's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Health Catalyst (HCAT) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Health Catalyst and its competitors. According to the industry distribution chart, Health Catalyst ranks #999999 out of 581 companies in the Healthcare Providers & Services industry.
Is Health Catalyst's Return-on-Tangible-Equity too high?
Health Catalyst's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Health Catalyst ranks #999999 out of 581 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Health Catalyst has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's Return-on-Tangible-Equity compare to SY and AMWL?
According to the Healthcare Providers & Services industry distribution chart, Health Catalyst ranks #999999 out of 581 companies for Return-on-Tangible-Equity. This places Health Catalyst in the lower half of its industry. The industry median Return-on-Tangible-Equity is 9.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.93, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Health Catalyst and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Catalyst's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $5.06, compared to a current price of $1.97 — trading 61.2% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Health Catalyst's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Health Catalyst (HCAT), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health Catalyst (HCAT) Overvalued in 2026?
Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued.
The current stock price of $1.97 is trading 61.2% below its estimated GF Value™ of $5.06.
GuruFocus considers Health Catalyst to be Possible Value Trap.
Key valuation signals for HCAT:
Return-on-Tangible-Equity: 0.00%
GF Value™: $5.06 vs. price of $1.97 (61.2% below fair value)
No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
44GF Score
Get the complete analysis for HCAT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCAT has been successfully added to your 
